Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Top Cited Papers
Open Access
- 1 April 2025
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (10) , 1198-1209
Abstract
PURPOSE: Denileukin diftitox (DD)-cxdl is a fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2. This phase III, multicenter, open-label, single-arm registrational trial evaluated the efficacy and safety of DD-cxdl in patients with relapsed/refractory (R/R) cutaneous T-cell lymphoma (CTCL). PATIENTS AND METHODS: In the main study, which followed a dose-finding lead-in, DD-cxdl was administered intravenously daily (5 days; 9 µg/kg/d once daily) every 21 days for up to eight cycles. Patients in the primary efficacy analysis set (PEAS) were required to have stage IA-IIIB CTCL (mycosis fungoides and/or Sézary syndrome) and at least ≥one previous systemic therapy. The primary efficacy end point was objective response rate (ORR) using the Global Response Score. Secondary end points were duration of response (DOR), time to response (TTR), skin tumor burden, and safety and tolerability. RESULTS: The PEAS included 69 patients (median age, 64.0 years). The ORR was 36.2% (95% CI, 25.0 to 48.7), including 8.7% with complete response. The median DOR was 8.9 months (95% CI, 5.0 to not estimable), and the median (Q1-Q3) TTR was 1.4 (0.7-2.1) months. A total of 84.4% of patients showed decreased skin tumor burden, with 48.4% showing a ≥50% decrease. Treatment-emergent adverse events (TEAEs) of special interest, most of which were grade 1 or 2, included infusion reaction (73.9%), hypersensitivity (68.1%), hepatotoxicity (36.2%), and capillary leak syndrome (20.3% [grade ≥3, 5.8%]). Other common TEAEs were nausea (43.5%) and fatigue (31.9%). CONCLUSION: Efficacy and safety results show that DD-cxdl would potentially fulfill a serious, unmet medical need for patients with R/R CTCL.Keywords
This publication has 22 references indexed in Scilit:
- Incidence Trends of Primary Cutaneous T-Cell Lymphoma in the US From 2000 to 2018JAMA Oncology, 2022
- Cutaneous T‐cell lymphomas: 2021 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2021
- Cutaneous T‐cell lymphomas—An update 2021Hematological Oncology, 2021
- Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphomaCancer Science, 2021
- The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T‐cell lymphomaBritish Journal of Haematology, 2020
- Overall Survival in Mycosis Fungoides: A Systematic Review and Meta-AnalysisJournal of Investigative Dermatology, 2020
- Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2018
- E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma: A phase I studyCancer Science, 2018
- Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomasBritish Journal of Dermatology, 2003
- Structure/function analysis of the transmembrane domain of DAB389-interleukin-2, an interleukin-2 receptor-targeted fusion toxin. The amphipathic helical region of the transmembrane domain is essential for the efficient delivery of the catalytic domain to the cytosol of target cellsJournal of Biological Chemistry, 1993